Search peptides, terms, sources/
Brain and mood

Selank

Also known as: TP-7

Synthetic tuftsin-derived peptide studied for anxiety. Not licensed in the UK; main human evidence is one active-comparator trial.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

2 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Selank is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials1 human trial · 1 animal

What is Selank?

Selank is a synthetic seven-amino-acid peptide derived from tuftsin, a natural immune-system peptide, studied for anxiety. It is not licensed in the UK, and the main human evidence is one active-comparator trial of 62 patients with generalised anxiety disorder and neurasthenia, without a placebo group.

It was engineered from tuftsin for greater stability in the body, and it has been studied mainly in mood and behaviour research.

Class
Tuftsin-derived anxiolytic/nootropic peptide
Origin
Fragment / derived
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Selank work?

Selank is based on tuftsin, an immune-system peptide. In a human trial it was linked to rising levels of a brain peptide called leu-enkephalin. In rats it changed activity of genes in the GABA system, which calms nerve activity. The authors suggest an indirect effect, not a direct receptor switch.

The mechanism in more detail

In a human clinical study of patients with generalized anxiety disorder and neurasthenia, decreased plasma levels of the enkephalin fragment tau(1-2) leu-enkephalin were reported in patients relative to controls, correlating with disease duration and symptom severity; these levels increased during Selank treatment, alongside reported clinical improvement. A separate rodent gene-expression study found that intranasal Selank altered expression of a substantial number of genes involved in GABAergic neurotransmission, with effects that correlated with, but were not identical to, those produced by GABA itself. The study authors interpreted this as evidence of allosteric modulation of the GABAergic system rather than direct receptor agonism.

Rat studies have also reported effects of Selank on brain-derived neurotrophic factor (BDNF) expression and on serotonin metabolism. No human data are cited for either. As with Semax, the core human evidence for Selank comes from a single trial conducted by a single research group, using an active-comparator design rather than a placebo control, and it has not been independently replicated outside that group.

Mechanisms and targets

Anxiolytic activity (non-sedative, as reported)Enkephalin-system modulationGABAergic modulation (proposed allosteric)Neurotrophic-factor upregulation (BDNF/NGF)Enkephalin metabolism pathwayGABAergic neurotransmission (allosteric target)

Classification and structure

Names
Selank; TP-7
Class
Tuftsin-derived anxiolytic/nootropic peptide
Origin
Fragment / derived
Structure
Thr-Lys-Pro-Arg-Pro-Gly-Pro (MW approx. 751.9 Da). Extends native tuftsin (Thr-Lys-Pro-Arg), a natural cleavage product of the Fc region of immunoglobulin G, with a C-terminal Pro-Gly-Pro tripeptide, engineered to dramatically improve metabolic (enzymatic) stability. Developed at the Institute of Molecular Genetics, Russian Academy of Sciences, in the 1990s.
Routes used in the research
Intranasal administration in both the human clinical trial literature and the rodent gene-expression study.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Selank has 2 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

2 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
02000

Anxiety trial versus medazepam Limited

In patients with generalized anxiety disorder and neurasthenia, Selank produced anxiolytic effects broadly comparable to the benzodiazepine-class comparator medazepam, with additional reported anti-asthenic and psychostimulant effects not seen with medazepam; treatment was associated with normalisation of plasma leu-enkephalin levels that had been reduced at baseline relative to disease severity/duration.

Study type
Human trial
Population
62 patients with GAD/neurasthenia (30 Selank, 32 medazepam, active-comparator design)
Source
1 Zozulia et al., 2008

Limitation: Active-comparator design (medazepam), not placebo-controlled, so the finding demonstrates comparability to an existing anxiolytic rather than superiority to no treatment; single trial, single research group, no replication by an independent group has been identified; sample size is modest (n=62).

Rat cortex gene expression Limited

Intranasal Selank administration altered expression of a substantial number of genes involved in GABAergic neurotransmission in rat frontal cortex at 1 and 3 hours post-dose, with effects correlated with GABA's own gene-expression signature at 1 hour but diverging by 3 hours.

Study type
Animal
Population
30 male Wistar rats (control, Selank, GABA groups)
Source
2 Volkova et al., 2016

Limitation: Single study; gene-expression-level data only, not a behavioural or receptor-binding confirmation of mechanism.

What safety findings have been reported?

1 safety finding is recorded for Selank. A short list does not mean a substance is safe; it reflects what has been studied and reported.

No adverse-event data identified

The published abstract of the GAD/neurasthenia trial reports no adverse-event data. No systematic human safety dataset for Selank has been identified.

Source
1 Zozulia et al., 2008

What is Selank's UK regulatory status?

Marketing authorisation
None. No MHRA marketing authorisation exists for Selank in the UK. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for Selank.
Prescription status
Not applicable; no licensed UK product exists to classify.
Medicine class
Would meet the Human Medicines Regulations 2012 (SI 2012/1916), Regulation 2 definition of a "medicinal product" if administered or marketed with a view to a pharmacological or physiological effect, an unlicensed medicinal product in the UK on that basis.
MHRA position
Unlicensed medicinal product if supplied or marketed for human administration with a therapeutic or anxiolytic purpose in the UK.
Authorised use
None in the UK.
Other restrictions
None identified beyond the standard unlicensed-medicine enforcement framework in the UK. A 2022 review (Deigin et al., Pharmaceutics) lists Selank among peptide drugs registered in Russia as an anxiolytic.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Selank is recorded as not licensed in the UK (checked 14 November 2026).

References

3 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Zozulia AA, Neznamov GG, Siuniakov TS, et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 108(4):38-48Human clinical trial · PMID 18454096 · Original ↗
  2. Volkova A, Shadrina M, Kolomin T, et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 7:31Animal-preclinical · DOI 10.3389/fphar.2016.00031 · PMID 26924987 · Original ↗
  3. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about Selank

What is Selank?

Selank is a synthetic seven-amino-acid peptide derived from tuftsin, a natural immune-system peptide, studied for anxiety. It is not licensed in the UK, and the main human evidence is one active-comparator trial of 62 patients with generalised anxiety disorder and neurasthenia, without a placebo group. Read what it is.

Is Selank licensed in the UK?

PeptGuru records Selank's UK status as: Not licensed in the UK. None. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Selank show?

PeptGuru records 2 research findings for Selank: 1 from a human trial and 1 from an animal study. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Selank?

1 safety finding is recorded, including: no adverse-event data identified. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Selank?

All 3 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Regulatory update · UK status now cites a dated MHRA database check.

How findings are graded: the grading method. All changes.

  • SemaxACTH heptapeptide analog

    Synthetic ACTH-derived peptide studied for brain function and stroke recovery. Not licensed in the UK; evidence is mainly rodent studies.

    Brain and moodHuman trialsEvidence reviewed
    LimitedNot licensed in the UK

Compare Selank with Semax

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.